查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447119

2030 年生技改良药市场预测：按产品类型、给药途径、分销管道、应用和地区进行的全球分析

Biobetters Market Forecasts to 2030 - Global Analysis By Product Type, By Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球生技改良药市场规模将达到 471.6 亿美元，预计到 2030 年将达到 930.8 亿美元，预测期内复合年增长率为 10.2%。

生技改良药是增强型生物製药，旨在提高便利性、安全性和有效性。这些复杂的生技药品寻求透过优化分子结构、配方和递送系统来提高原始治疗方法的功效。 生技改良药寻求透过提高患者依从性和最大限度地减少副作用来提供更好的治疗效果并降低医疗成本，从而克服现有治疗方法的缺点。

根据爱思唯尔 (Elsevier) 2022 年 1 月发表的一篇论文， 生技改良药通常是经过改进的生物药品，具有更好的药物动力学，而糖基化和聚乙二醇化等技术可以帮助开发生技改良药是最常见的策略。

医疗保健支出增加

医疗保健基础设施和服务方面财政支出的增加支持了对先进生物製药解决方案（包括生技改良药）的需求。随着医疗保健投资的增加，人们越来越关注优化治疗结果和成本效益。具有更高功效和安全性的生技改良药符合这一趋势，并为医疗保健相关人员提供了一种策略工具，可以在不断发展的医疗保健领域中改善患者的治疗结果并更有效地管理医疗保健成本。

开发成本高

生技改良药市场面临一个主要限制：开发成本高。增强生物製药的复杂过程需要广泛的研究、严格的测试和法规遵循，需要大量的财务投资。对于市场参与企业来说，这些高成本构成了挑战，并可能限制创新和市场进入。

原创生技药品专利到期增加

一旦专利到期，它就为生物製药公司开发具有增强功能的改进版本打开了大门，例如提高功效或减少副作用。这促进了创新、竞争和市场扩张。透过利用专利到期，公司可以更有效地应对监管环境并提供具有成本效益的替代方案。因此，专利到期为生物企业提供了一个策略窗口，并促进了生物製药产业的动态和竞争格局。

严格的监管要求

严格的监管要求对生技改良药市场构成了重大威胁，需要详尽的文件记录和广泛的临床试验。合规性挑战可能会延长开发时间并增加成本，从而阻止潜在的市场进入者。严格的核准流程在确保病人安全的同时，可能会阻碍创新并抑制市场竞争。

COVID-19 的影响：

COVID-19 的疫情对生技改良药市场既有正面的影响，也有负面的影响。对医疗保健创新的日益关注加速了研究和开发，但药品供应链的中断和优先事项的转移导致了延误和挑战。此外，经济不确定性和资源重新配置正在影响投资模式。整体而言，这场大流行凸显了生技改良药市场敏捷性和弹性的重要性。

在预测期内，注射剂领域预计将成为最大的领域

由于生物製药中对注射配方的偏好，加上其快速且准确的药物输送，预计注射剂领域将在预测期内主导生技改良药市场。此外，注射剂通常是复杂生技药品给药的首选。需要持续治疗性介入的慢性疾病的增加进一步推动了对注射生物製剂的需求并巩固了其在市场中的地位。

预计糖尿病产业在预测期内复合年增长率最高

预计在预测期内，糖尿病细分市场将在生技改良药市场中呈现最高成长。这种增长是由于全球糖尿病盛行率不断上升，需要更强大、更有效的生物製药解决方案。 生技改良药预计将越来越多地用于糖尿病治疗，因为它有望提高疗效并减少副作用。因此，糖尿病领域预计将经历显着增长，为不断发展的生物製药领域提供利润丰厚的机会。

比最大的地区

由于活跃的研发活动、成熟的生物製药产业以及慢性病的高盛行率，北美预计将引领生技改良药市场。该地区先进的医疗保健基础设施和法律规范有利于高效的产品核可。此外，策略联盟和对技术进步的关注有助于市场主导地位。由于专注于创新和增加对医疗保健的投资，预计北美将继续保持其作为生技改良药领域进步和市场成长驱动力的突出地位。

复合年增长率最高的地区：

由于医疗保健基础设施的扩大、研发投资的增加以及对先进生物製药解决方案的需求不断增长，预计亚太地区生技改良药市场将快速成长。该地区庞大的患者群体和日益增强的个人化医疗意识进一步支持了市场扩张。策略联盟、有利的法规环境和快速发展的生物技术产业正在加速生技改良药的采用，使亚太地区成为不断发展的生物製药领域的关键参与者。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球生技改良药市场：依产品类型

  • 双特异性抗体
  • 融合蛋白
  • 颗粒细胞增生因子(G-CSF)
  • 单株抗体
  • 聚乙二醇化蛋白
  • 其他产品类型

第六章 全球生技改良药市场：依管理途径

  • 注射
    • 皮下的
    • 静脉
    • 肌肉注射
  • 吸入
  • 其他给药途径

第七章 全球生技改良药市场：依通路

  • 医院药房
  • 网路药房
  • 零售药房
  • 其他分销管道

第八章全球生技改良药市场：依应用分类

  • 肿瘤学
    • 乳癌
    • 大肠直肠癌
    • 白血病
    • 淋巴瘤
    • 非小细胞肺癌
    • 其他类型的肿瘤
  • 自体免疫疾病
    • 发炎性肠道疾病
    • 多发性硬化症
    • 干癣
    • 类风湿性关节炎
    • 其他自体免疫疾病
  • 糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 感染疾病
  • 其他用途

第九章全球生技改良药市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon Ltd.
  • Biogen Inc.
  • Celltrion Inc.
  • Eli Lilly and Company
  • Genentech, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: SMRC25380

According to Stratistics MRC, the Global Biobetters Market is accounted for $47.16 billion in 2023 and is expected to reach $93.08 billion by 2030 growing at a CAGR of 10.2% during the forecast period. Biobetters are enhanced biopharmaceutical medications designed to improve convenience, safety, or efficacy. These sophisticated biologics seek to improve upon the efficacy of the original treatments through the optimization of molecular structures, formulations, or delivery systems. Biobetters work to overcome the shortcomings of existing treatments by providing better therapeutic results and possibly lowering medical expenses by increasing patient compliance and minimizing side effects.

According to an article published by Elsevier in January 2022, biobetters are improved biological drugs that usually have better pharmacokinetics, and techniques such as glycosylation and PEGylation are the most common strategies to develop biobetters.

Market Dynamics:

Driver:

Rising healthcare expenditure

The increasing financial commitment to healthcare infrastructure and services underscores the demand for advanced biopharmaceutical solutions, including biobetters. As healthcare investments rise, there is a growing emphasis on optimizing therapeutic outcomes and cost-effectiveness. Biobetters, with their enhanced efficacy and safety profiles, align with this trend, providing a strategic avenue for healthcare stakeholders to achieve improved patient outcomes and manage healthcare costs more efficiently, reinforcing their significance in the evolving healthcare landscape.

Restraint:

High development costs

The biobetters market faces a significant restraint in the form of high development. The intricate process of enhancing biopharmaceuticals demands extensive research, rigorous testing, and regulatory compliance, leading to substantial financial investments. These elevated costs present a challenge for market participants, potentially limiting innovation and market entry.

Opportunity:

Growing patent expiries of original biologics

When patents expire, it opens avenues for biopharmaceutical companies to develop improved versions with enhanced features, such as increased efficacy or reduced side effects. This fosters innovation, competition, and market expansion. By leveraging the expiration of patents, companies can navigate the regulatory landscape more efficiently and offer cost-effective alternatives. As a result, the patent expiries create a strategic window for Biobetters, fostering a dynamic and competitive landscape in the biopharmaceutical industry.

Threat:

Stringent regulatory requirements

Stringent regulatory requirements pose a significant threat to the biobetters market, demanding exhaustive documentation and extensive clinical trials. Compliance challenges may prolong development timelines and escalate costs, deterring potential market entrants. The rigorous approval processes, while ensuring patient safety, can hinder innovation and stifle competition in the market.

Covid-19 Impact:

The COVID-19 pandemic has both positively and negatively impacted the biobetters market. While heightened focus on healthcare innovation has accelerated research and development, disruptions in the pharmaceutical supply chain and shifting priorities have led to delays and challenges. Additionally, economic uncertainties and resource reallocations have affected investment patterns. Overall, the pandemic has emphasized the importance of agility and resilience in the biobetters market.

The injection segment is expected to be the largest during the forecast period

The injection segment is anticipated to dominate the biobetters market throughout the forecast period due to the preference for injectable formulations in biopharmaceuticals, coupled with their rapid and precise drug delivery, which contributes to this dominance. Additionally, injections are often favored for administering complex biologics. The growth in chronic diseases requiring sustained therapeutic interventions further propels the demand for injectable biobetters, solidifying their position in the market.

The diabetes segment is expected to have the highest CAGR during the forecast period

The diabetes segment is poised to exhibit the highest growth in the biobetters market during the forecast period. This growth is attributed to the escalating global prevalence of diabetes, necessitating enhanced and more effective biopharmaceutical solutions. Biobetters, with their potential for improved efficacy and reduced side effects, are likely to witness increased adoption in diabetes treatment. As a result, the diabetes segment is anticipated to experience substantial growth, presenting lucrative opportunities in the evolving biopharmaceutical landscape.

Region with largest share:

North America is poised to lead the biobetters market due to robust research and development activities, a well-established biopharmaceutical industry, and a high prevalence of chronic diseases. The region's advanced healthcare infrastructure and regulatory frameworks facilitate efficient product approvals. Additionally, strategic collaborations and a focus on technological advancements contribute to market dominance. With a strong emphasis on innovation and increasing healthcare investments, North America is expected to maintain its prominent position in driving advancements and market growth in the biobetters sector.

Region with highest CAGR:

The Asia Pacific region is poised for rapid growth in the biobetters market owing to expanding healthcare infrastructure, increasing investments in research and development, and a rising demand for advanced biopharmaceutical solutions. The region's large patient population and growing awareness of personalized medicine further drive market expansion. Strategic collaborations, favorable regulatory environments, and a burgeoning biotechnology sector contribute to the anticipated acceleration of biobetter adoption, making Asia Pacific a key player in the evolving biopharmaceutical landscape.

Key players in the market

Some of the key players in Biobetters market include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biocon Ltd., Biogen Inc., Celltrion Inc., Eli Lilly and Company, Genentech, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Developments:

In January 2024, AbbVie strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design novel cell and gene therapy products, strengthening AstraZeneca's growing offering in this space. As part of the agreement, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 candidate products could be explored for development.

In September 2022, Novartis announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will bolster its capacity and capabilities for early technical development of biologics. Spanning both drug substance and drug product development, the multi-year investment will be implemented across existing Novartis locations in Switzerland, Slovenia and Austria, strengthening Novartis ability to deliver on the increasing growth and diversity of its early-stage biotherapeutics portfolio.

Product Types Covered:

  • Bispecific Antibodies
  • Fusion Proteins
  • Granulocyte Colony Stimulating Factor (G-CSF)
  • Monoclonal Antibodies
  • Pegylated Proteins
  • Other Product Types

Route of Administrations Covered:

  • Injection
  • Inhalation
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Applications Covered:

  • Oncology
  • Autoimmune Diseases
  • Diabetes
  • Infectious Diseases
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biobetters Market, By Product Type

  • 5.1 Introduction
  • 5.2 Bispecific Antibodies
  • 5.3 Fusion Proteins
  • 5.4 Granulocyte Colony Stimulating Factor (G-CSF)
  • 5.5 Monoclonal Antibodies
  • 5.6 Pegylated Proteins
  • 5.7 Other Product Types

6 Global Biobetters Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Injection
    • 6.2.1 Subcutaneous
    • 6.2.2 Intravenous
    • 6.2.3 Intramuscular
  • 6.3 Inhalation
  • 6.4 Other Route of Administrations

7 Global Biobetters Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Online Pharmacies
  • 7.4 Retail Pharmacies
  • 7.5 Other Distribution Channels

8 Global Biobetters Market, By Application

  • 8.1 Introduction
  • 8.2 Oncology
    • 8.2.1 Breast Cancer
    • 8.2.2 Colorectal Cancer
    • 8.2.3 Leukemia
    • 8.2.4 Lymphoma
    • 8.2.5 Non-small Cell Lung Cancer
    • 8.2.6 Other Oncology Types
  • 8.3 Autoimmune Diseases
    • 8.3.1 Inflammatory Bowel Disease
    • 8.3.2 Multiple Sclerosis
    • 8.3.3 Psoriasis
    • 8.3.4 Rheumatoid arthritis
    • 8.3.5 Other Autoimmune Diseases
  • 8.4 Diabetes
    • 8.6.1 Type 1 Diabetes
    • 8.6.2 Type 2 Diabetes
  • 8.5 Infectious Diseases
  • 8.6 Other Applications

9 Global Biobetters Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AbbVie Inc.
  • 11.2 Amgen Inc.
  • 11.3 AstraZeneca PLC
  • 11.4 Biocon Ltd.
  • 11.5 Biogen Inc.
  • 11.6 Celltrion Inc.
  • 11.7 Eli Lilly and Company
  • 11.8 Genentech, Inc.
  • 11.9 Johnson & Johnson
  • 11.10 Merck & Co., Inc.
  • 11.11 Novartis AG
  • 11.12 Pfizer Inc.
  • 11.13 Regeneron Pharmaceuticals, Inc.
  • 11.14 Samsung Bioepis Co., Ltd.
  • 11.15 Sanofi S.A.
  • 11.16 Takeda Pharmaceutical Company Limited

List of Tables

  • Table 1 Global Biobetters Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biobetters Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Biobetters Market Outlook, By Bispecific Antibodies (2021-2030) ($MN)
  • Table 4 Global Biobetters Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 5 Global Biobetters Market Outlook, By Granulocyte Colony Stimulating Factor (G-CSF) (2021-2030) ($MN)
  • Table 6 Global Biobetters Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 7 Global Biobetters Market Outlook, By Pegylated Proteins (2021-2030) ($MN)
  • Table 8 Global Biobetters Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 9 Global Biobetters Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 10 Global Biobetters Market Outlook, By Injection (2021-2030) ($MN)
  • Table 11 Global Biobetters Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 12 Global Biobetters Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 13 Global Biobetters Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 14 Global Biobetters Market Outlook, By Inhalation (2021-2030) ($MN)
  • Table 15 Global Biobetters Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 16 Global Biobetters Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Biobetters Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 18 Global Biobetters Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 19 Global Biobetters Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 Global Biobetters Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 21 Global Biobetters Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Biobetters Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 23 Global Biobetters Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 24 Global Biobetters Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 25 Global Biobetters Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 26 Global Biobetters Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 27 Global Biobetters Market Outlook, By Non-small Cell Lung Cancer (2021-2030) ($MN)
  • Table 28 Global Biobetters Market Outlook, By Other Oncology Types (2021-2030) ($MN)
  • Table 29 Global Biobetters Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 30 Global Biobetters Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 31 Global Biobetters Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 32 Global Biobetters Market Outlook, By Psoriasis (2021-2030) ($MN)
  • Table 33 Global Biobetters Market Outlook, By Rheumatoid arthritis (2021-2030) ($MN)
  • Table 34 Global Biobetters Market Outlook, By Other Autoimmune Diseases (2021-2030) ($MN)
  • Table 35 Global Biobetters Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 36 Global Biobetters Market Outlook, By Type 1 Diabetes (2021-2030) ($MN)
  • Table 37 Global Biobetters Market Outlook, By Type 2 Diabetes (2021-2030) ($MN)
  • Table 38 Global Biobetters Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 39 Global Biobetters Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.